Reply to: No effect of resistance-associated substitutions in patients with rare HCV subtypes following treatment with sofosbuvir-containing regimens. Journal Of Hepatology. https://doi.org/10.1016/j.jhep.2017.11.044 (Original work published 2018)
. (2018).